Roche's Alzheimer's antibody "removes amyloid plaques from brain"
This article was originally published in Scrip
Executive Summary
The first clinical data published for Roche's investigational monoclonal antibody gantenerumab, for the treatment of the early stages of Alzheimer's disease show that the product removes amyloid plaques from the brain of patients with the condition.